Data as of Sep 30
| +0.10 / +1.47%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 9.87, with a high estimate of 10.00 and a low estimate of 9.06. The median estimate represents a +42.97% increase from the last price of 6.90.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.